Fish Principal Gwilym Attwell Authors Article for Life Science Leader, “Intellectual Property Do’s and Don’ts for Early-Stage Life Sciences Companies”
Fish & Richardson Trademark & Copyright Thoughts
FEBRUARY 1, 2022
Early-stage life sciences companies typically focus their time and resources on developing their core products, positioning them for commercial success, and, if applicable, obtaining Food and Drug Administration (FDA) approval. Intellectual property (IP) protection is often further down their list of priorities. This is a mistake.
52 
Let's personalize your content